{"id":"regenecyte","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Transient elevation of inflammatory markers"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"The drug involves harvesting a patient's own bone marrow stem cells, expanding them ex vivo, and reinfusing them to stimulate regenerative processes in damaged tissues. The mechanism relies on the immunomodulatory and paracrine effects of mesenchymal stem cells, which secrete growth factors and cytokines that promote angiogenesis, reduce inflammation, and support tissue healing.","oneSentence":"REGENECYTE is a cell therapy that uses expanded autologous bone marrow-derived stem cells to promote tissue regeneration and repair.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:31:42.745Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic heart failure"},{"name":"Myocardial infarction"}]},"trialDetails":[{"nctId":"NCT07332338","phase":"","title":"Expanded Access Use of Human Umbilical Cord Blood (REGENECYTE) Infusion in Patients With Chronic Fatigue of Post-COVID Condition","status":"AVAILABLE","sponsor":"StemCyte, Inc.","startDate":"","conditions":"Post-COVID-19 Condition, Post-COVID Condition, Post-COVID Syndrome","enrollment":""},{"nctId":"NCT07184385","phase":"PHASE3","title":"A Study of Human Umbilical Cord Blood (REGENECYTE) Infusion in Patients With Post-COVID Condition","status":"NOT_YET_RECRUITING","sponsor":"StemCyte, Inc.","startDate":"2026-03-31","conditions":"Long COVID, Post-COVID-19 Condition, Post-COVID Syndrome","enrollment":60},{"nctId":"NCT05682560","phase":"PHASE2","title":"Human Umbilical Cord Blood (RegeneCyte) Infusion in Patients with Post-COVID Syndrome","status":"COMPLETED","sponsor":"StemCyte, Inc.","startDate":"2023-05-04","conditions":"Long COVID, Post-COVID Syndrome, Post COVID-19 Condition","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"REGENECYTE","genericName":"REGENECYTE","companyName":"StemCyte, Inc.","companyId":"stemcyte-inc","modality":"Biologic","firstApprovalDate":"","aiSummary":"REGENECYTE is a cell therapy that uses expanded autologous bone marrow-derived stem cells to promote tissue regeneration and repair. Used for Chronic heart failure, Myocardial infarction.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}